
Flagship British project to boost global surgical standards under threat of closure
The Global Surgery Unit (GSU), launched in 2017 by the Royal College of Surgeons, conducts large-scale studies across a network of 120 countries to find ways of making surgical care both more effective and accessible, particularly in developing countries.
Every year more than four million people die from conditions that could be treated with surgical procedures – a greater number of deaths than HIV/Aids, malaria, and TB combined – yet it remains one of the most neglected components of global health.
In recent years the GSU has conducted some of the biggest surgical research studies in history, and claims to be the largest global research network in science. In 2021 it set a Guinness World Record with a landmark study on the impact of Covid-19 on surgical patients that involved collaboration from over 15,000 scientists and researchers.
But it could now be forced to close in June next year when its current funding runs out, said Professor Dion Morton, GSU co-lead and the Barling Chair of Surgery at the University of Birmingham, which co-created the unit.
'They've already funded us through to June 2026, they can't take that back – [but] if they could, they would,' he told The Telegraph.
Prof Morton said the GSU 'has been run on a shoestring' since its launch, costing only around £20 million and focusing on a public health intervention that plays a vital role in nearly every area of medicine.
Some 28 per cent of the global disease burden stems from conditions that are treatable with surgery – from infections and trauma wounds, to blindness and maternal health.
Improving surgery is also a key component of the fight against antimicrobial resistance (AMR), which kills more than 1.1 million people around the world every year, including 35,000 in the UK alone. By preventing and managing infections, it helps to reduce unnecessary antibiotic use.
The GSU, which involves 40,000 surgeons across 120 countries, conducts large-scale trials to tackle major global surgical challenges across many countries at the same time.
The initiative has driven advancements in low-cost and practical interventions to improve surgical care in low-resource settings - innovations that are also feeding back into surgical practices in the UK.
One of the GSU's landmark studies, known as the CHEETAH trial, conducted across three continents, found that simply changing gloves and instruments before wound closure prevents one in seven wound infections. This practice has now been adopted into routine practice in Britain and around the world.
Another major initiative, the EAGLE trial, tested in 70 countries, introduced a standardised medical checklist to improve outcomes in bowel surgery.
'Global surgical care is probably the greatest world health challenge today and the one that we are currently failing to meet,' said Prof Morton.
'It is a fundamental part of the health system and if we're going to provide effective global health care and we must strengthen the whole system, it's not enough to just treat single conditions.'
A 'bottom up approach' to transforming care
Experts have warned that Labour's decision to slash its overseas aid budget by around £6 billion, including a 46 per cent drop in health related spending, could reverse vital progress in some of the world's most vulnerable regions.
Shrinking development budgets means politicians are focusing on threats like single disease interventions, pandemics, and conflict.
'There's a tendency in global health to look backwards…but it's not actually treating the whole health system. It's not addressing the real need in the world. And I think that this is a mistake,' said Prof Morton.
Last month, The Telegraph reported that the Fleming Fund, a major £265 million British programme designed to tackle AMR in the developing world, is being closed by Labour's aid cuts.
Sir Jeremy Hunt, the former health secretary, told The Telegraph that the move 'directly puts our national security at risk'.
Prof Morton also challenged a common misconception that surgery is 'only a crisis treatment of last resort', adding that it 'is not simply something that's carried out in an operating theatre.'
Some global health and development institutions have come under increasing scrutiny for perpetuating so called 'colonial power dynamics'. But Prof Morton said the GSU takes 'a bottom up approach to transforming care.'
Instead of allowing Western high-income countries to dictate the agenda, the GSU prioritises collaboration with local surgeons and healthcare providers in poorer countries to co-create interventions tailored to their specific needs.
'In some respects, it bypasses the policy makers and allows the clinicians to improve the care for their patients, and that's the key element in the global surgery network that makes it different from anything else,' he added.
The consequences of not having access to surgery are profound.
It means that every year millions of people die from treatable conditions, such as hernia repair and obstructed labour, which is treated with basic procedures like caesarian sections.
The burden falls heaviest on the world's poorest. Some 93 per cent of people in sub-Saharan Africa don't have access to basic surgical care. One survey suggests that 40 per cent of donated surgical equipment in poor countries is out of service.
Yet, some surgeries can rank among the most cost-effective of all health interventions, such as cataract removal, which reverses blindness at a remarkably low cost.
Research suggests expanding access to surgical care in poorer countries would boost the global economy by $80 billion annually.
Training enough surgeons, anaesthetists and obstetricians remains a key challenge to widening access, with over 160 million patients unable to receive surgery each year.
In higher income countries such as the UK, there are around 35 surgical specialists per 100,000 people, whereas in Bangladesh there are 1.7 per 100,000 people.
Only 26 per cent of countries have met the Global Surgery 2030 goal to ensure everyone has access to essential surgery within two hours.
Yet basic training can make a huge difference. Research shows that trained junior staff, such as clinical officers with around three years of experience, can perform caesarean sections just as safely as doctors.
Prof Morton, who has an Officer of the Order of the British Empire (OBE) for services to innovation in the NHS, warned that the UK's aid cuts will have profound global consequences.
'It will likely result in the suspension of national surgical obstetric and anaesthetic plans in most countries around the world,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Edinburgh Live
2 minutes ago
- Edinburgh Live
Fuerteventura hotel responds after British dad died from 'half-cooked chicken'
Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info A luxury four-star Fuerteventura resort has defended itself following the tragic death of a British holidaymaker who consumed "half-cooked" chicken during his stay. Occidental Jandia Playa has today maintained it operates "a strict food hygiene and safety protocol" and adheres to all regulations. The establishment has issued a robust statement after an inquest revealed Leslie Green, a father from Bolton, Greater Manchester, developed the bacterial infection salmonella at the all-inclusive resort. Last week's hearing was told the 70 year old gentleman consumed undercooked poultry at Occidental Jandia Playa on Fuerteventura, one of Spain's Canary Islands. Nevertheless, the Barceló Hotel Group, which operates the Occidental Jandia Playa, stated yesterday that no salmonella has been identified at the property in the past twelve months, reports the Mirror. The spokesperson commented: "We also hold certificates from the aforementioned external audit company confirming that no salmonella has been detected at the hotel in the last twelve months. These audits and controls reflect our ongoing commitment to the health and safety of guests." (Image: Irwin Mitchell / SWNS) Yet Mr Green and his 60 year old spouse Julie had exclusively dined at the Occidental Jandia Playa throughout their Fuerteventura break last October. Rochdale Coroner's Court was told Mr Green, a retired delivery driver, developed symptoms including diarrhoea several days into the trip and his condition worsened. The coroner determined Mr Green had perished from food poisoning acquired whilst on holiday after consuming partially cooked chicken. The Barcelo Hotel Group, established in Spain in 1981, expressed its deep sorrow over the incident. The full statement reads: "The Barceló Hotel Group deeply regrets the death of a guest at our Fuerteventura hotel in November 2024. "On behalf of the entire group, we would like to extend our deepest condolences to the guest's family and loved ones and reiterate our firm commitment to the safety and well-being of our customers. "The Barceló Hotel Group has a strict food hygiene and safety protocol that includes rigorous internal controls and periodic external audits performed by an independent company renowned in food safety. Join Edinburgh Live's Whatsapp Community here and get the latest news sentstraight to your messages. "This control system guarantees compliance with applicable regulations and our company's stringent quality standards. We also hold certificates from the aforementioned external audit company confirming that no salmonella has been detected at the hotel in the last twelve months. These audits and controls reflect our ongoing commitment to the health and safety of guests." The Greens were on a Jet2 holiday when the tragedy occurred. Jet2 stated it would be "inappropriate" to comment due to an ongoing legal claim, but offered its "thoughts and condolences" to the Green family. Following the inquest, Mrs Green, a retired nurse, said: "I still struggle to comprehend how we went on holiday, but Leslie didn't come home... He was my best friend and life without him will never be the same."


BBC News
3 minutes ago
- BBC News
White Wood butterflies found in Powys after decades-long absence
One of the rarest butterflies in the UK has returned Wales, decades after last being seen in the endangered Wood White, known for its delicate cream colour and striped antennae, was recorded at four sites in Powys by the Butterfly Conservation, including a female laying species used to have a permanent colony in south-east Wales but died out several decades ago due to a destruction of habitat, with only some "sporadic sightings" Conservation said butterflies had suffered in recent years "because of human actions" but now there was new hope for conservationists, with a "real success story" in the new species in Wales. Since 1979, the species' abundance has decreased by 82% at its few remaining sites. Butterfly Conservation said the new arrivals "almost certainly" come from sites just over the border in Shropshire, where targeted conservation work has been ongoing to maintain Wood White charity said its conservation team saw at least four individuals, including a female laying eggs, at Natural Resources Wales (NRW) sites at now plan to do further surveys next spring and are in contact with NRW to discuss managing roadside verges along forestry plantation roads. The news comes after a host of "surprising butterfly and moth activity", the charity said, much of it linked to this year's record-breaking Conservation have recorded 18 species of butterfly emerging at least two weeks earlier than average, with a further 24 species at least a week Dr Dan Hoare, Butterfly Conservation director of nature recovery, said while the charity loved to see butterflies and moths doing well in the UK, there were "going to be winners and losers from the very rapid climate change we're experiencing".Dr Hoare added: "One way we can increase the number of climate winners is by managing habitats positively so that threatened species can benefit as well as widespread mobile species."That means creating and maintaining good quality, connected habitat at a landscape scale, which Butterfly Conservation has been doing for years and will continue to do."


Reuters
3 minutes ago
- Reuters
Focus: To stay on weight-loss drugs, US patients cut doses and maybe vacations
Aug 13 (Reuters) - Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight, opens new tab. Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. "A significant number of my patients now pay cash," said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. "People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two." More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. "My new company does not cover GLP-1s, so now I am in a kind of purgatory," Kibasova said. "I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight." The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription "cold turkey," so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. Peters said she uses "every technique in the book" to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. "Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance," Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug "really don't want to go off of it when they recognize that it has such a value to them." Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. "We are in a dip where people are dropping coverage," Fitch said, adding that the direct-to-consumer options are an "upper-ish middle-class thing."